The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

NCT04699123 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

159

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG: NC318 800 mg
DRUG: NC318 400 mg
DRUG: Pembrolizumab

Sponsor

Yale University

Collaborators

[object Object]
[object Object]
[object Object]